title: Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome.
abstract: OBJECTIVE
  To compare two forms of continuous renal replacement therapy, continuous venovenous hemofiltration (CVVH) vs. continuous venovenous hemodialysis (CVVHD), in terms of the removal of inflammatory mediators from the blood of patients with systemic inflammatory response syndrome and acute renal failure.
  
  
  METHODS
  Randomized crossover, clinical study.
  
  
  METHODS
  University teaching hospital.
  
  
  METHODS
  Thirteen patients with systemic inflammatory response syndrome and acute renal failure receiving continuous renal replacement therapy.
  
  
  METHODS
  Patients were randomized to receive either convective clearance using CVVH or diffusive clearance using CVVHD for the first 24 hrs, followed by the other modality for 24 hrs. All treatments utilized AN69 hemofilters. CVVH was performed with an ultrafiltration rate of 2 L/hr and CVVHD with a dialysis outflow rate of 2 L/hr.
  
  
  RESULTS
  Plasma and ultrafiltrate concentrations of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-10, and sL-selectin were measured at 0, 1, 3, 6, 12, and 24 hrs by radioimmunoassay. Plasma endotoxin concentrations were also measured at 0, 12, and 24 hrs by chromogenic assay. CVVH was associated with a 13% decrease in plasma TNF-alpha concentrations compared with a 23% increase while on CVVHD (p < .05). Mean plasma concentrations of IL-6, IL-10, and sL-selectin were unchanged over time and between therapies. Only minimal amounts of mediators were recovered in the effluents with either therapy except for IL-6. The clearances for IL-6 were different between therapies, 1.9+/-0.8 (SD) mL/min for CVVHD and 3.3+/-1.5 mL/min for CVVH, (p< .01). Plasma endotoxin concentrations were not different between therapies.
  
  
  CONCLUSIONS
  CVVH resulted in a decrease in plasma TNF-alpha concentrations as compared with CVVHD, while the type of transport mechanism used did not influence plasma concentrations of IL-6, IL-10, soluble L-selectin, or endotoxin. Differences in clearance for IL-6 between CVVH and CVVHD did not translate into significant changes in circulating IL-6 concentrations.
authors.affiliation: Department of Anesthesiology/Critical Care Medicine, University of Pittsburgh Medical Center, PA, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Kellum
authors.forename: J P
authors.initials: JP
authors.lastname: Johnson
authors.forename: D
authors.initials: D
authors.lastname: Kramer
authors.forename: P
authors.initials: P
authors.lastname: Palevsky
authors.forename: J J
authors.initials: JJ
authors.lastname: Brady
authors.forename: M R
authors.initials: MR
authors.lastname: Pinsky
mesh_terms: D058186:Acute Kidney Injury / Q000150:complications / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D018481:Convection; D018592:Cross-Over Studies; D004058:Diffusion; D004731:Endotoxins / Q000097:blood; D017583:Hemodiafiltration / Q000379:methods*; D006440:Hemofiltration / Q000379:methods*; D006801:Humans; D016753:Interleukin-10 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D019041:L-Selectin / Q000097:blood; D018746:Systemic Inflammatory Response Syndrome / Q000150:complications / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D004731:Endotoxins; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D019041:L-Selectin; D016753:Interleukin-10